AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT00858832 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methergine
Description: Scheduled methergine 0.2 mg PO every 6hrs for duration of postpartum stay
Study NCT01787071 — intervention group
Intervention type: OTHER
Intervention: Fluid challenge
Description: Administration of red blood cell transfusions or fresh frozen plasma is not considered as a fluid challenge.
Study NCT02966457 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Colistimethate Sodium
Description: Selective oral intestinal decolonization
Study NCT03883061 — intervention group
Intervention type: OTHER
Intervention: regular medical treatment
Description: regular medical treatment
Study NCT03475225 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cholecalciferol
Description: Cholecalciferol delivery
Study NCT03475225 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Oral
Description: manufactured to mimic Cholecalciferol
Study NCT04048577 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dosing Interruption of Natalizumab
Description: Planned 12 week dosing interruption of natalizumab
Study NCT01329757 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: GH
Description: Administration of a subcutaneously injected daily dose of GH (0.4mg)for 1 year
Study NCT01329757 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Administration of a subcutaneously injected daily dose of placebo for 1 year
Study NCT01564979 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: preseptal injection of botulinum toxin type A
Description: botulinum toxin type A (Botox)2.5 units, 5 points
Study NCT01564979 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pretarsal injection of Botulinum toxin type A
Description: Botulinum toxin type A 2,5 units, 5 points
Study NCT02235818 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Kinesiotape
Description: Pre-cut kinesiotape for tennis elbow, spidertech.com, applied on wrist extensors starting above elbow and ending at distal one third of forearm
Study NCT02235818 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Counterforce elbow brace
Description: Applied over the wrist extensor muscle mass, had velcro for adjustment, comfortable grip as reported by patient was used to adjust the brace
Study NCT03384992 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Diaphragmatic breathing and relaxation
Description: Education on physiological effects of anxiety, instructions in diaphragmatic breathing and relaxation techniques, and audio-recordings 5-15 minutes in length that provide guided relaxation exercises (autogenic, imagery-based and progressive muscle relaxation).
Study NCT03384992 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cognitive restructuring
Description: Education on the thought-emotion connection and exercises designed to better understand cognitions associated with increased anxiety and tools to evaluate and replace anxiety-generating cognitions. Includes an interactive tool (thought record) participants complete to facilitate this process.
Study NCT03384992 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Scheduled worry practice
Description: Education on the association between avoidance and increased anxiety, and instructions on actively thinking about feared events to reduce avoidance and engage healthy coping strategies. Interactive tool includes a video-based guided worry practice session and an interactive worksheet and timer.
Study NCT03384992 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Telephone coaching
Description: BCS will receive 5 TeleCoaching calls over a period of 4 weeks, to include one introductory phone call, followed by 4 calls focused each week on the current CSM; if the participant is not randomized to a CSM, TeleCoaching will provide reflective listening and encouragement.
Study NCT03384992 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Usual care
Description: Includes general health, diet-general information and diet-BCSS (breast cancer survivor-specific) information.
Study NCT01504503 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Donepezil Hydrochloride
Description: Donepezil Hydrochloride Tablets 10 mg
Study NCT01504503 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Aricept
Description: Aricept 10 mg Tablets
Study NCT04551443 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Intravenous infusion placebo
Description: Intravenous infusion placebo or WJMSCs in patients with AMI
Study NCT04551443 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Intravenous infusion placebo
Description: Intravenous infusion placebo or WJMSCs in patients with AMI
Study NCT04551443 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Intravenous infusion WJMSCs
Description: Intravenous infusion WJMSCs or placebo in patients with AMI
Study NCT04551443 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Intravenous infusion WJMSCs
Description: Intravenous infusion WJMSCs or placebo in patients with AMI
Study NCT04073615 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rivoceranib
Description: Film-coated tablets
Study NCT04073615 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trifluridine/Tipiracil
Description: Film-coated tablets
Study NCT04073615 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Trifluridine/Tipiracil
Description: Film-coated tablets
Study NCT04401059 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Elemene plus first or third generation EGFR-TKIs
Description: Elemene Injectable Emulsion: 20ml: 88mg, 6 injections each time, once a day, continuous intravenous drip for 5 days. Continue to use Elemene Oral Emulsion. For specific usage, refer to the drug label.~Elemene Oral Emulsion: 20ml: 176mg, 1 dose each time, 3 times a day. Use the Elemene Oral Emulsions until the disease progresses, the intolerable toxicity, the patient withdraws from the study, or dies for any reason.~First or third generation EGFR-TKIs: refer to the drug label.
Study NCT04565938 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Application of adhesive for the restoration of dental lesions with resin composite
Description: 1. Mechanical removal of sclerotic dentin with a round bur~2. Enamel beveling~3. Enamel (30sec) and dentin (15sec) etching with phosphoric acid~4. Application of ExciTE (Ivoclar/Vivadent, AG, Shaan, Lichtenstein) and curing for 10sec with 800mW/cm2 light intensity (Cure TC-01, Spring Health Products, Inc, Norristown, PA, USA)~5. Composite-resin application using a transparent cervical matrix (Kerr-Hawe, Orange, CA, USA) and curing for 40sec~6. Finishing and polishing
Study NCT04565938 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Application of adhesive for the restoration of dental lesions with resin composite
Description: 1. Mechanical removal of sclerotic dentin with a round bur~2. Enamel beveling~3. Application of AdheSE One (Ivoclar/Vivadent, AG, Shaan, Lichtenstein) and curing for 10sec~4. Composite-resin application using a transparent cervical matrix and curing for 40sec~5. Finishing and polishing
Study NCT04565938 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Application of adhesive for the restoration of dental lesions with resin composite
Description: 1. Mechanical removal of sclerotic dentin with a round bur~2. Enamel beveling~3. Enamel (30sec) etching with phosphoric acid~4. Application of AdheSE One and curing for 10sec~5. Composite-resin application using a transparent cervical matrix and curing for 40sec~6. Finishing and polishing
Study NCT04396275 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Food-1
Description: Cooked whole navy beans (300 kcal)
Study NCT04396275 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Food-2
Description: Cooked whole yellow split peas (300 kcal)
Study NCT04396275 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Food-3
Description: Cooked rice considered as control (300 kcal)
Study NCT02156661 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oxytocin
Study NCT02156661 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Oxytocin
Study NCT04401059 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: First or third generation EGFR-TKIs
Description: refer to the drug label.
Study NCT04516304 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Placebo
Description: 4 tablets/d (2 in the morning and 2 in the evening)
Study NCT04516304 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 4 tablets/d (2 in the morning and 2 in the evening)
Study NCT04516304 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: S-equol
Description: 4 tablets/d (2 in the morning and 2 in the evening), providing 10 mg S-equol total a day Other Names: •Equelle®
Study NCT04516304 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: S-equol
Description: 4 tablets/d (2 in the morning and 2 in the evening), providing 10 mg S-equol total a day Other Names: •Equelle®
Study NCT01495026 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dutasteride (0.5mg, fasted state)
Description: Open-label, randomized, single dose, multi-stage, cross-over study
Study NCT01495026 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dutasteride (0.5mg, fed state)
Description: Commercial formulation of Dutasteride 0.5mg
Study NCT01495026 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fixed dose combination capsule containing dutasteride 0.5mg and tamsulosin 0.2mg (fasted state)
Description: FDC with 85%, 65% and 0% of the dose as enteric-coated pellets and with X and/or Y% of the dose as enteric-coated pellets (X and Y to be determined from PK results from Stage 1)
Study NCT01495026 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fixed dose combination capsule containing dutasteride 0.5mg and tamsulosin 0.2mg (fasted state)
Description: FDC containing faster-release enteric-coated pellets
Study NCT01495026 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fixed dose combination capsule containing dutasteride 0.5mg and tamsulosin 0.2mg (fasted state)
Description: FDC bioequivalent to Harnal-D tablets
Study NCT01495026 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fixed dose combination capsule containing dutasteride 0.5mg and tamsulosin 0.2mg (fed state)
Description: FDC bioequivalent to Harnal-D tablets
Study NCT01495026 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Harnal-D Tablets with water (fasted state)
Description: Commercial formulation of Harnal-D Tablets
Study NCT01495026 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Harnal-D Tablets with water (fed state)
Description: Commercial formulation of Harnal-D Tablets
Study NCT01495026 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Harnal-D tablets without water (fasted state)
Description: Commercial formulation of Harnal-D Tablets
Study NCT03142607 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metronidazole gel
Description: 1% Metronidazole gel
Study NCT03142607 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Chlorhexidine Gluconate
Description: 0.2% Chlorhexidene gluconate gel
Study NCT01627704 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Fluoroestradiol (18F)
Description: 2-4 MBq/kg body mass, one single IV injection
Study NCT03040024 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ketamine
Description: Ketamine will be administered intravenously after administration of general anesthesia and prior to the first surgical incision.
Study NCT03040024 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo will be administered intravenously after administration of general anesthesia and prior to the first surgical incision.
Study NCT03040024 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Electroencephalogram (EEG)
Description: A processed EEG device will be used during the surgical procedure to gather raw EEG data for off line analysis among patients developing post-operative delirium.
Study NCT03040024 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Electroencephalogram (EEG)
Description: A processed EEG device will be used during the surgical procedure to gather raw EEG data for off line analysis among patients developing post-operative delirium.
Study NCT00794287 — intervention group
Intervention type: OTHER
Intervention: Taking blood samples
Description: No intervention is done. Only blood samples are taken.
Study NCT02318602 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cannabidiol Oral Solution
Description: An oral solution containing pharmaceutical grade cannabidiol (nonplant-based).
Study NCT03736044 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TNF-blockers suspension in patients with rheumatoid arthritis
Description: in patients treated with anti-TNF the intervention consisted in anti-TNF drug withdrawal, after a preliminary careful examination of remission status; a 18 months (at least) follow up was performed.
Study NCT02950506 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: transcranial direct current stimulation
Description: The anode will be placed over left DLPFC at F3, according to the 10-20 international system for EEG electrode placement. The cathode will be placed over the contralateral supraorbital area. They will be placed via two saline soaked electrode sponges (3 cm x 4.5 cm).After electrodes have been placed, the participants will be instructed to log into CRT software using a unique patient identifier. The CRT software that will be used will be Cogmed working memory training program (Pearson Education, Inc.)Active tDCS will be applied at a ramp-like fashion from 0 to 2mA over 10 seconds, and will be ramped down for the last 10 seconds of stimulation. Active tDCS will last 20 minutes each session. The sham procedure involves only 30 seconds of stimulation at 2mA.
Study NCT00796341 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: PIPELLE ENDOMETRIAL SAMPLING
Description: Pipelle endometrial sampling will be done twice between 7th to 10th day and 24th to 26th d in the cycle prior to IVF.
Study NCT01193712 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: temporary left ventricular endocardial pacing
Description: a temporary pacemaker lead will be introduced through the aortic valve to evaluate the effect of left ventricular endocardial pacing. Four different pacing sites (basal and apical septal, basal and apical lateral) will be investigated with measurement of LV dP/dtmax. Afterwards, the endocardial pacing lead will be removed.
Study NCT05217472 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ravaglimab
Description: Intravenous Injection
Study NCT05217472 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ravagalimab
Description: Subcutaneous Injection
Study NCT05217472 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Intravenous Injection
Study NCT05217472 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Subcutaneous Injection
Study NCT03505762 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Given IV
Study NCT03505762 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cyclophosphamide
Description: Given IV
Study NCT03505762 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxorubicin Hydrochloride
Description: Given IV
Study NCT03505762 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Doxorubicin Hydrochloride
Description: Given IV
Study NCT03505762 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study NCT03505762 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study NCT02950506 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Cognitive Remediation Therapy
Description: The CRT software that will be used will be Cogmed working memory training program (Pearson Education, Inc.). Cogmed is a targeted computerized training program that has been shown to improve working memory and attention. (Spencer-Smith 2015).
Study NCT02950506 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Cognitive Remediation Therapy
Description: The CRT software that will be used will be Cogmed working memory training program (Pearson Education, Inc.). Cogmed is a targeted computerized training program that has been shown to improve working memory and attention. (Spencer-Smith 2015).
Study NCT00666744 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Family Mediated Exercise Therapy
Description: 35 minutes of lower limb exercises to be completed by the person with stroke on a daily basis with the assistance of their family for a period of 8 weeks.
Study NCT03280329 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Generalized Music therapy
Description: Patients will receive broadcasted music via speakers in their room from 7am to 11pm, from admission to discharge
Study NCT03280329 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Personalized Music therapy
Description: Patients will receive music via earphones after specific music therapist advice, for 2 hours per day, from admission to discharge
Study NCT03505762 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisone
Description: Given PO
Study NCT03505762 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Prednisone
Description: Given PO
Study NCT03505762 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality-of-Life Assessment
Description: Ancillary correlative
Study NCT03505762 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Quality-of-Life Assessment
Description: Ancillary correlative
Study NCT03505762 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies
Study NCT03505762 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Questionnaire Administration
Description: Ancillary studies
Study NCT03505762 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: Given IV
Study NCT03505762 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Rituximab
Description: Given IV
Study NCT03505762 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vincristine Sulfate
Description: Given IV
Study NCT03505762 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vincristine Sulfate
Description: Given IV
Study NCT01508312 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: brentuximab vedotin (SGN-35)
Description: Patients will receive 2 cycles of weekly brentuximab vedotin, 1.2mg/kg on days 1, 8, and 15 of each 28 day cycle. Patients with pre-treatment positive bone marrow biopsies will have repeat bone marrow biopsies if the PET scan is negative. FDG-PET/CT will be repeated after 2 cycles of treatment within 1 week of the last dose of cycle 2. Patients with persistent abnormalities on FDG-PET/CT following 2 cycles of brentuximab vedotin will receive 2 cycles of augmented ICE. The first cycle of augmented ICE will be initiated 7-14 days after the last dose of SGN-35. FDG-PET/CT will be repeated within 7-14 days following the second cycle of augmented ICE. Stem cell mobilization can be performed following the first or second cycle of augmented ICE.
Study NCT01508312 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Brentuximab Vedotin (SGN-35)
Description: Patients will receive 2 cycles of weekly brentuximab vedotin, 1.2mg/kg on days 1, 8, and 15 of each 28 day cycle. FDG-PET/CT will be repeated after 2 cycles of treatment within 1 week of the last dose of cycle 2. Patients with pre-treatment positive bone marrow biopsies will have repeat bone marrow biopsies if the PET scan is negative. Patients with normalization of FDG-PET/CT and negative bone marrow biopsies following 2 cycles of brentuximab vedotin will undergo stem cell mobilization in preparation for ASCT.
Study NCT03150329 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study NCT03150329 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Given IV
Study NCT03150329 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vorinostat
Description: Given PO
Study NCT02443077 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Autologous Bone Marrow Transplantation
Description: Undergo autologous hematopoietic progenitor cells or bone marrow transplant
Study NCT02443077 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Autologous Bone Marrow Transplantation
Description: Undergo autologous hematopoietic progenitor cells or bone marrow transplant
Study NCT02443077 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Autologous Hematopoietic Stem Cell Transplantation
Description: Undergo autologous hematopoietic progenitor cells or bone marrow transplant
Study NCT02085811 — intervention group
Intervention type: OTHER
Intervention: radiography standard
Study NCT02443077 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Autologous Hematopoietic Stem Cell Transplantation
Description: Undergo autologous hematopoietic progenitor cells or bone marrow transplant
Study NCT02443077 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carmustine
Description: Given IV